{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:16Z","timestamp":1787008996971,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing antibiotic resistance of Helicobacter pylori poses challenges in selecting effective eradication therapies for patients with gastric cancer. This study aimed to assess the antibiotic resistance patterns of clinical H. pylori strains isolated from gastric cancer patients, to guide H. pylori eradication strategies for those with residual gastric mucosa after gastrectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 115 consecutive patients with gastric cancer who had a positive 13C urea breath test, all of whom were scheduled for gastric resection at West China Hospital of Sichuan University. Gastric mucosa samples were collected for pathological examination, H. pylori culture, and susceptibility testing using E-test and disk diffusion methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 115 specimens, 86 H. pylori strains were cultured (74.8% culture rate). Of the 86 patients (59 males, 27 females; median age 59, range 34\u201379) with successful H. pylori isolation, histopathology revealed 37 intestinal-type, 27 diffuse-type, 9 mixed-type, and 13 unclassified gastric cancers. Sixty-one patients underwent distal gastrectomy, and 25 had radical total gastrectomy. Notably, 12 patients were diagnosed at \u226445 years, including 9 females, all with signet ring cell carcinoma. Antibiotic resistance rates were rifampicin (RIF) (69.8%), metronidazole (MTZ) (75.6%), clarithromycin (CLR) (41.9%), levofloxacin (LEV) (32.6%), amoxicillin (AML) (2.3%), tetracycline (TET) (1.2%), and furazolidone (FZD) (0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>H. pylori isolates from gastric cancer patients exhibited high resistance to RIF, MTZ, CLR, and LEV, but negligible resistance to AML, FZD, and TET. Given the compromised health status and need for concurrent therapies in these patients, AML- and\/or minocycline-based regimens may represent a practical and effective treatment option for H. pylori eradication in gastric cancer patients with residual gastric mucosa after distal gastrectomy, to reduce the risk of metachronous gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf400","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:57:50Z","timestamp":1754049470000},"page":"S412-S417","source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial Resistance Patterns of Clinical\n                    <i>Helicobacter pylori<\/i>\n                    Isolates From Gastric Cancer Patients"],"prefix":"10.1093","volume":"232","author":[{"given":"Yupei","family":"Zhang","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-9231","authenticated-orcid":false,"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy\/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Gastric Cancer Center, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Shen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-4010","authenticated-orcid":false,"given":"Alfred","family":"Tay","sequence":"additional","affiliation":[{"name":"Helicobacter pylori Research Laboratory, Marshall Centre for Infectious Diseases Research and Training, School of Biomedical Sciences, University of Western Australia , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Marshall","sequence":"additional","affiliation":[{"name":"Helicobacter pylori Research Laboratory, Marshall Centre for Infectious Diseases Research and Training, School of Biomedical Sciences, University of Western Australia , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3528-0448","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112010500947400_jiaf400-B1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"2025112010500947400_jiaf400-B2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"2025112010500947400_jiaf400-B3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/apt.14424","article-title":"Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication\u2014a prospective study for up to 10 years","volume":"47","author":"Hwang","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010500947400_jiaf400-B4","doi-asserted-by":"crossref","first-page":"e13042","DOI":"10.1111\/hel.13042","article-title":"Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication?","volume":"29","author":"Liang","year":"2024","journal-title":"Helicobacter"},{"key":"2025112010500947400_jiaf400-B5","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1136\/gutjnl-2017-315363","article-title":"Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population","volume":"67","author":"Doorakkers","year":"2018","journal-title":"Gut"},{"key":"2025112010500947400_jiaf400-B6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa1708423","article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer","volume":"378","author":"Choi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112010500947400_jiaf400-B7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.gie.2018.05.009","article-title":"Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial","volume":"88","author":"Choi","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"2025112010500947400_jiaf400-B8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"2025112010500947400_jiaf400-B9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1473-3099(17)30005-1","article-title":"How long until routine Helicobacter pylori antimicrobial susceptibility testing?","volume":"17","author":"Montes","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025112010500947400_jiaf400-B10","doi-asserted-by":"crossref","first-page":"e12597","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"2025112010500947400_jiaf400-B11","doi-asserted-by":"crossref","first-page":"e12703","DOI":"10.1111\/hel.12703","article-title":"Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori","volume":"25","author":"Tang","year":"2020","journal-title":"Helicobacter"},{"key":"2025112010500947400_jiaf400-B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/hel.12145","article-title":"Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods","volume":"19","author":"Eun","year":"2014","journal-title":"Helicobacter"},{"key":"2025112010500947400_jiaf400-B13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","article-title":"Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota","volume":"67","author":"Ferreira","year":"2018","journal-title":"Gut"},{"key":"2025112010500947400_jiaf400-B14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.chom.2023.06.016","article-title":"A single-nucleotide polymorphism in Helicobacter pylori promotes gastric cancer development","volume":"31","author":"Sharafutdinov","year":"2023","journal-title":"Cell Host Microbe"},{"key":"2025112010500947400_jiaf400-B15","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","article-title":"Hereditary diffuse gastric cancer: updated clinical practice guidelines","volume":"21","author":"Blair","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025112010500947400_jiaf400-B16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/17474124.2018.1496017","article-title":"Helicobacter pylori drug resistance: therapy changes and challenges","volume":"12","author":"Flores-Trevi\u00f1o","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025112010500947400_jiaf400-B17","doi-asserted-by":"crossref","first-page":"e13103","DOI":"10.1111\/hel.13103","article-title":"Global primary antibiotic resistance rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis","volume":"29","author":"Yu","year":"2024","journal-title":"Helicobacter"},{"key":"2025112010500947400_jiaf400-B18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112010500947400_jiaf400-B19","doi-asserted-by":"crossref","first-page":"107325","DOI":"10.1016\/j.ijantimicag.2024.107325","article-title":"Antibiotic resistance of Helicobacter pylori in Mainland China: a focus on geographic differences through systematic review and meta-analysis","volume":"64","author":"Zeng","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025112010500947400_jiaf400-B20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12866-022-02613-y","article-title":"Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet autonomous region, China","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Microbiol"},{"key":"2025112010500947400_jiaf400-B21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2217\/fmb-2020-0206","article-title":"Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population","volume":"15","author":"Tang","year":"2020","journal-title":"Future Microbiol"},{"key":"2025112010500947400_jiaf400-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13756-019-0632-1","article-title":"Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations","volume":"8","author":"Liu","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025112010500947400_jiaf400-B23","doi-asserted-by":"crossref","first-page":"w14630","DOI":"10.4414\/smw.2018.14630","article-title":"In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates","volume":"148","author":"Wang","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"2025112010500947400_jiaf400-B24","doi-asserted-by":"crossref","first-page":"780.e5","DOI":"10.1016\/j.cmi.2017.11.010","article-title":"Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study","volume":"24","author":"Liu","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025112010500947400_jiaf400-B25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40249-021-00806-7","article-title":"Changes in newly notified cases and control of tuberculosis in China: time-series analysis of surveillance data","volume":"10","author":"Wang","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"2025112010500947400_jiaf400-B26","doi-asserted-by":"crossref","first-page":"2348505","DOI":"10.1080\/22221751.2024.2348505","article-title":"Transmission characteristics in Tuberculosis by WGS: nationwide cross-sectional surveillance in China","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"2025112010500947400_jiaf400-B27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010500947400_jiaf400-B28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2023.11.001","article-title":"Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan","volume":"138","author":"Kuo","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"Suppl 5","key":"2025112010500947400_jiaf400-B29","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1093\/infdis\/jiac417","article-title":"The inappropriateness of using rifampicin E-test to predict rifabutin resistance in Helicobacter pylori","volume":"226","author":"Yang","year":"2022","journal-title":"J Infect Dis"},{"key":"2025112010500947400_jiaf400-B30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/CM9.0000000000002629","article-title":"Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: a randomized controlled trial","volume":"136","author":"Suo","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2025112010500947400_jiaf400-B31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/microorganisms12030429","article-title":"Minocycline\/amoxicillin-based bismuth quadruple therapy for Helicobacter pylori eradication: a pilot study","volume":"12","author":"You","year":"2024","journal-title":"Microorganisms"},{"key":"2025112010500947400_jiaf400-B32","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2147\/IDR.S457618","article-title":"The efficacy and safety of minocycline-containing quadruple therapies against Helicobacter pylori Infection: a retrospective cohort study","volume":"17","author":"Si","year":"2024","journal-title":"Infect Drug Resist"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S412\/65408919\/jiaf400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S412\/65408919\/jiaf400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:50:19Z","timestamp":1763653819000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/Supplement_4\/S412\/8329319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":32,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,11,20]]},"published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf400","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,11,15]]}}}